Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Soft tissue sarcoma, adult
Stage/Subtype:  stage III adult soft tissue sarcoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 34 for your search:
Start Over
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15677, NCI-2015-01298, 2015-000134-30, I5B-MC-JGDJ, NCT02451943
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105SAR101, NCI-2014-00305, NCT01975519
Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SARC023, NCI-2014-02429, CDMRP-NF120087, NCT02008877
Talimogene Laherparepvec and Preoperative Radiation Therapy in Treating Patients with Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201504731, NCI-2015-01193, 20139075, NCT02453191
Sapanisertib or Pazopanib Hydrochloride in Treating Patients with Locally Advanced or Metastatic Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091304, NCI-2015-01929, NCT02601209
Proton Beam Radiation Therapy in Treating Patients with Previously Untreated Childhood Rhabdomyosarcoma
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: 04-188, NCI-2011-03349, NCT00592592
Gemcitabine Hydrochloride and Docetaxel or Pazopanib Hydrochloride in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: 101644, NCI-2012-00675, MUSC 101644, MUSC CTO 101644, PAZ115785, PZP115785, NCT01593748
Alisertib in Treating Patients with Advanced or Metastatic Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091102, NCI-2012-01991, CALGB-A091102, CDR0000737403, NCT01653028
Cabozantinib-S-Malate in Treating Patients with Refractory Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0044, NCI-2012-03124, 09-25-0099, 121088, 130044, P121088, P9284_A07PAMDREVW01, 9284, NCT01755195
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Regorafenib in Treating Patients with Previously Treated, Metastatic, or Locally Advanced Angiosarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 13S02, NCI-2013-02278, ONC-2013-129, STU00087654, NCT02048722
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9464, NCI-2013-02414, NCT02050919
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and over
Trial IDs: 09-090, NCI-2010-01242, NCT01099644
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma
Phase: Phase I
Type: Treatment
Age: 4 to 55
Trial IDs: ADP 04511, NCI-2015-00410, NCI-2013-01481, UPCC 04511, NCT01343043
Pazopanib Hydrochloride and Abexinostat in Treating Patients with Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11955, NCI-2012-01142, UCSF Protocol No. 11955, NCT01543763
Dasatinib and Ipilimumab in Treating Patients with Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-083, NCI-2012-01165, CDR0000737378, 9172, NCT01643278
Bevacizumab, Doxorubicin Hydrochloride, and Radiation Therapy in Treating Patients with Soft Tissue Sarcomas That Can Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-396, NCI-2013-01105, ML28479, NCT01746238
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ID-LV305-2013-001, NCI-2014-01153, NCT02122861
NY-ESO-1-Specific T-cells in Treating Patients with Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2721.00, NCI-2014-02154, 2721, NCT02319824
Start Over